A HEARING THAT REACHES FAR BEYOND WASHINGTON
JaFaJ Intelligence Brief | August 2026
KEY JUDGMENTS
- The July 29, 2026 Senate testimony of former National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci marks a new phase in congressional oversight of pandemic-era decision making, laboratory research, and government transparency.
- Although the hearing focused on U.S. COVID-19 policy, its implications extend well beyond domestic politics. Governments operating high-containment biological laboratories—including those throughout the Middle East—are likely to face renewed scrutiny regarding research oversight, foreign partnerships, and biosafety governance.
- The central issue is no longer simply the origin of COVID-19. Increasingly, policymakers are asking a broader question: Who oversees biological research capable of affecting global security, and are existing safeguards adequate?
- For the Middle East, where biotechnology has become an important component of economic diversification, national security, and public health preparedness, this debate may become increasingly consequential over the next decade.
INTRODUCTION
Few congressional hearings generate international attention years after the crisis that prompted them. The July 29, 2026 testimony of Dr. Anthony Fauci before the Senate Homeland Security and Governmental Affairs Committee did precisely that.
The hearing followed the public release of more than 1,000 pages from Fauci’s pandemic-era journals by Committee Chairman Senator Rand Paul (R-KY), renewing debate over the federal government’s response to COVID-19, internal deliberations during the pandemic, and oversight of biomedical research. During the hearing, Fauci invoked his Fifth Amendment right in response to questioning, explaining in an opening statement that he believed the proceedings were designed to expose him to potential criminal liability rather than to conduct neutral oversight.
Regardless of political perspective, the hearing represents a significant milestone in the continuing reassessment of the COVID-19 era. Six years after the pandemic reshaped governments, economies, and societies worldwide, legislatures are shifting from emergency response toward institutional accountability. Questions once confined to epidemiologists and public-health officials are now central topics of legislative inquiry, national security analysis, and foreign policy.
The debate is also evolving. It is no longer focused solely on whether specific decisions were correct. Increasingly, lawmakers are examining how high-risk biological research is funded, supervised, documented, and communicated to the public.
FROM PANDEMIC RESPONSE TO GOVERNANCE
The COVID-19 pandemic exposed vulnerabilities extending well beyond public health. Governments discovered that disease outbreaks can disrupt supply chains, alter military readiness, reshape elections, strain diplomatic relations, and impose costs measured in trillions of dollars.
Consequently, biological research has moved from being viewed primarily as a medical issue to becoming an element of national security.
This transformation is not unique to the United States. Across Europe, Asia, and the Middle East, governments have expanded investments in infectious disease research, genomic surveillance, vaccine development, and laboratory infrastructure. The same laboratories that investigate emerging pathogens, however, often possess capabilities that are inherently dual-use—meaning the knowledge, equipment, and techniques employed for legitimate defensive purposes may also have potential offensive applications if misused.
This dual-use nature has long challenged policymakers. Unlike nuclear facilities, where specialized equipment and fissile materials are relatively identifiable, modern biological research frequently uses technologies common to universities, hospitals, pharmaceutical companies, and public-health agencies. Distinguishing legitimate defensive research from prohibited offensive activities is therefore considerably more complex.
The Biological Weapons Convention (BWC), which entered into force in 1975, prohibits the development, production, and stockpiling of biological weapons. However, unlike many nuclear arms-control agreements, the BWC does not include a comprehensive international verification or inspection regime. Compliance therefore depends largely on national implementation, voluntary confidence-building measures, and diplomatic engagement rather than routine inspections. This structural gap has been recognized by experts for decades and remains a recurring topic in international biosecurity discussions.
WHY THE HEARING MATTERS OUTSIDE THE UNITED STATES
The significance of the Fauci hearing does not depend on whether one agrees with the positions advanced by Senator Paul, Dr. Fauci, or other members of Congress.
Its importance lies elsewhere.
For the first time since the height of the pandemic, Congress has signaled that laboratory governance itself—not merely pandemic policy—has become an enduring subject of legislative oversight. Issues discussed during the hearing included government recordkeeping, internal deliberations, congressional transparency, scientific accountability, and the management of sensitive biomedical research.
These questions resonate internationally because many nations—including close U.S. allies—operate advanced biological laboratories, collaborate with foreign governments, and participate in multinational disease-surveillance networks. If Washington adopts stricter oversight requirements for federally funded biological research or overseas research partnerships, similar governance debates could emerge elsewhere.
This is particularly relevant in the Middle East, where governments have invested heavily in biotechnology as part of broader national development strategies. Israel maintains sophisticated biodefense and biomedical research capabilities. Saudi Arabia has significantly expanded infectious-disease research following repeated outbreaks of Middle East Respiratory Syndrome (MERS). The United Arab Emirates and Qatar are investing in genomics, precision medicine, and advanced public-health infrastructure. Egypt continues to play a major regional role in disease surveillance through internationally recognized research institutions.
Collectively, these investments reflect a broader regional trend: biotechnology is increasingly viewed not only as a public-health necessity but also as a strategic national capability.
THE CENTRAL QUESTION
The most important question raised by the Senate hearing may not concern COVID-19 itself.
Instead, it is this:
How should democratic governments oversee research involving dangerous pathogens while preserving scientific innovation, protecting national security, and maintaining public confidence?
That question applies equally to Washington, Jerusalem, Riyadh, Abu Dhabi, Doha, Cairo, Ankara, and Tehran.
The answer will likely shape the next generation of biosecurity policy.
JAFAJ STRATEGIC ASSESSMENT
The July 2026 Fauci hearing is unlikely to produce immediate changes in global biological research. It is, however, likely to influence how legislatures view laboratory oversight. Congressional investigations often serve as policy catalysts, even when they do not result in immediate legislation. The broader effect may be a gradual shift toward greater documentation requirements, stronger reporting obligations, expanded funding oversight, and more rigorous review of international biological research partnerships.
For Middle Eastern governments seeking to expand biotechnology sectors while attracting foreign investment and scientific collaboration, transparency may become a strategic asset rather than merely a regulatory obligation. Nations able to demonstrate robust biosafety standards, independent oversight, and clear governance frameworks will likely be better positioned to build international scientific partnerships in an era of increasing geopolitical competition.
MAPPING THE MIDDLE EAST’S BIOLOGICAL RESEARCH INFRASTRUCTURE
KEY JUDGMENTS
- The Middle East possesses a larger and more sophisticated biological research infrastructure than is commonly understood.
- Most publicly identified facilities conduct legitimate public health, vaccine, genomics, agricultural, veterinary, or biodefense research. Their existence alone is not evidence of offensive biological weapons programs.
- The strategic challenge lies in the dual-use nature of modern biotechnology: many of the same laboratories capable of developing vaccines are also technically capable of handling dangerous pathogens under strict biosafety controls.
- As Congress reexamines U.S. oversight of biological research following the Fauci hearing, governments throughout the Middle East may face increasing international questions regarding laboratory governance, transparency, foreign partnerships, and biosafety standards.
THE REGION’S QUIET BIOTECH REVOLUTION
For decades, discussion of Middle Eastern security has centered on missiles, nuclear programs, drones, terrorism, and energy. Far less attention has been paid to another strategic capability that has quietly expanded across the region: biotechnology.
COVID-19 accelerated investments in infectious-disease surveillance, genomic sequencing, vaccine development, molecular diagnostics, and advanced laboratory infrastructure. Long before COVID-19, outbreaks of SARS, H1N1 influenza, Ebola, and especially Middle East Respiratory Syndrome (MERS) convinced regional governments that biological preparedness was becoming a national security issue rather than simply a public-health concern.
Today, virtually every major Middle Eastern power operates advanced biological research laboratories. The overwhelming majority exist for legitimate scientific and medical purposes. Nevertheless, because biotechnology is inherently dual-use, these same facilities have become increasingly important from a strategic and intelligence perspective.
ISRAEL
Israel Institute for Biological Research (IIBR)
Location: Ness Ziona, southeast of Tel Aviv
The Israel Institute for Biological Research is widely regarded as Israel’s premier government biological research institution. Although much of its work remains classified, the institute publicly states that it conducts research involving:
- vaccines
- therapeutic drugs
- infectious diseases
- biological detection systems
- chemical defense
- biological defense
The institute played a significant role during the COVID-19 pandemic through vaccine and antibody research and has long supported Israel’s broader biodefense capabilities. Israel neither confirms nor denies many aspects of its national defense research, contributing to longstanding international speculation. Publicly available evidence, however, primarily documents defensive and biomedical research rather than offensive biological weapons activities.
Strategic Assessment
Israel’s biological research capability is among the most advanced in the Middle East. The country benefits from close collaboration among government agencies, universities, hospitals, biotechnology firms, and its defense sector. Congressional debates in Washington over transparency and laboratory oversight are unlikely to alter Israel’s research priorities, but they could influence future expectations for disclosure and international scientific cooperation.
SAUDI ARABIA
King Abdullah University of Science and Technology (KAUST)
Location: Thuwal, Red Sea Coast
KAUST has emerged as one of the region’s premier scientific research institutions. Its Bioscience Core Laboratory supports advanced genomic sequencing, proteomics, molecular biology, bioinformatics, and biomedical research.^5 Research is supported through extensive bioscience core facilities and institutional biosafety oversight.
Following repeated MERS outbreaks, Saudi Arabia significantly expanded investment in vaccine development and infectious-disease preparedness. One major initiative was the Saudi Vaccine and Biomanufacturing Center (SVBC), established at KAUST’s Research and Technology Park to develop vaccines and biopharmaceuticals while strengthening domestic manufacturing capacity against epidemic threats such as MERS-CoV.^6
Saudi Arabia’s biological infrastructure now extends beyond public health into biotechnology, pharmaceutical manufacturing, and genomic medicine, aligning with the Kingdom’s Vision 2030 economic diversification strategy.
Strategic Assessment
Saudi Arabia increasingly views biotechnology as an economic sector rather than merely a medical discipline. Investments in vaccine production reduce dependence on foreign suppliers while creating opportunities for regional scientific leadership. These developments are consistent with global trends and, based on publicly available information, remain focused on civilian and defensive applications.
UNITED ARAB EMIRATES
The UAE has invested heavily in genomic medicine, precision healthcare, artificial intelligence, and biomedical innovation.
Major centers include:
- Khalifa University
- Abu Dhabi Public Health Centre
- national genomic sequencing initiatives
Research emphasizes:
- genomic surveillance
- infectious disease monitoring
- precision medicine
- artificial intelligence applications in healthcare
Unlike several neighboring states, the UAE has deliberately integrated biotechnology into its broader innovation economy, viewing life sciences as a strategic industry alongside artificial intelligence and advanced manufacturing.
Strategic Assessment
The UAE is positioning itself as a regional biotechnology hub capable of attracting foreign investment and multinational pharmaceutical partnerships. Greater congressional attention to international biological collaborations may encourage even stronger governance frameworks as Abu Dhabi seeks to maintain investor confidence.
QATAR
Qatar has developed one of the Middle East’s most ambitious precision medicine programs.
Key institutions include:
- Qatar Genome Programme
- Qatar University biotechnology research centers
- Sidra Medicine
- Hamad Medical Corporation
The Qatar Genome Programme has produced one of the world’s largest population-specific genomic databases, designed to support personalized medicine and biomedical research within the Gulf region.^7
Research priorities include:
- human genetics
- cancer research
- infectious diseases
- molecular diagnostics
- precision medicine
Strategic Assessment
Qatar’s emphasis differs from traditional biodefense programs. Rather than focusing primarily on dangerous pathogens, Doha has invested heavily in genomic medicine and biomedical innovation, supporting its long-term objective of becoming a regional knowledge economy.
EGYPT
Naval Medical Research Unit Three (NAMRU-3)
Location: Cairo
NAMRU-3 is one of the oldest continuously operating infectious-disease research organizations in the region. It conducts surveillance and research on:
- influenza
- antimicrobial resistance
- vector-borne diseases
- emerging infectious diseases
Egypt also maintains an extensive public-health laboratory network supporting national disease surveillance and regional cooperation.
Strategic Assessment
Egypt occupies a unique position because of its geographic links among Africa, the Middle East, and Europe. Disease surveillance conducted in Egypt often contributes to regional early-warning systems, making Cairo an important participant in international public-health cooperation.
JORDAN
Jordan’s biological research infrastructure is comparatively modest but strategically significant.
Major institutions support:
- tuberculosis research
- zoonotic diseases
- refugee health
- regional epidemiological surveillance
Jordan frequently partners with international organizations because of its proximity to conflict zones experiencing large-scale population displacement.
IRAN
Iran maintains one of the Middle East’s largest biomedical research systems.
Pasteur Institute of Iran
Location: Tehran
Established in 1920, the Pasteur Institute of Iran conducts research involving infectious diseases, diagnostics, vaccines, and public health.^8
Razi Vaccine and Serum Research Institute
Location: Karaj (with additional facilities elsewhere)
Research includes:
- human vaccines
- veterinary vaccines
- livestock diseases
- biotechnology
- serum production
Iran has invested heavily in domestic vaccine production and biotechnology, driven in part by international sanctions that have encouraged self-sufficiency.
Strategic Assessment
Iran views biotechnology as a strategic national capability with implications for healthcare, agriculture, and industrial resilience. While Western governments have periodically expressed concerns regarding aspects of Iran’s broader weapons programs, publicly available evidence regarding these civilian biomedical institutions primarily reflects vaccine production, infectious-disease research, and public-health activities. Allegations concerning prohibited biological weapons work have not been publicly substantiated with evidence comparable to that available for historical offensive programs in countries such as the former Soviet Union or Iraq.
REGIONAL OBSERVATION
One conclusion emerges clearly from the region’s laboratory landscape.
The Middle East is not experiencing a biological weapons race.
It is experiencing a biotechnology race.
Governments increasingly recognize that biological research influences national resilience, pharmaceutical independence, food security, economic diversification, and strategic competitiveness. Laboratories once viewed solely as medical facilities are now part of broader national innovation strategies.
That evolution explains why congressional oversight debates in Washington may resonate far beyond the United States. As legislators examine transparency, funding, and governance of high-containment research, allied governments may encounter similar questions from their own legislatures, publics, and international partners.
THE TRANSPARENCY PROBLEM — WHY BIOLOGICAL RESEARCH IS THE HARDEST WEAPONS PROGRAM TO VERIFY
KEY JUDGMENTS
- Unlike nuclear and chemical weapons programs, biological research cannot be easily distinguished as peaceful or military solely by examining a laboratory’s equipment or facilities.
- The central challenge confronting policymakers is verification, not simply prohibition. The same technologies that support vaccine development, disease surveillance, and pharmaceutical research may also have dual-use potential.
- The Biological Weapons Convention (BWC) prohibits offensive biological weapons but does not contain a comprehensive international inspection regime comparable to those governing nuclear or chemical weapons.^9
- As governments invest in biotechnology, synthetic biology, and artificial intelligence, pressure is likely to increase for stronger transparency measures, voluntary reporting, and internationally accepted biosafety standards.
THE FUNDAMENTAL DILEMMA
One lesson emerged repeatedly during the COVID-19 pandemic:
Modern biology has become strategically important.
The same laboratories that sequence viruses, develop vaccines, manufacture therapeutics, and monitor emerging diseases also possess equipment capable of handling some of the world’s most dangerous pathogens. That reality creates a governance challenge unlike any other area of arms control.
Unlike uranium enrichment facilities or ballistic missile production plants, biological laboratories are inherently dual-use. Their scientific value depends on studying dangerous organisms under controlled conditions. As a result, the existence of a sophisticated laboratory does not reveal its intent.
A Biosafety Level 3 (BSL-3) laboratory conducting influenza surveillance may use equipment that appears remarkably similar to one studying anthrax or other dangerous pathogens for defensive purposes. Even higher-containment laboratories employ technologies that are widely available in advanced biomedical research institutions.
Consequently, intent—not equipment—is often the defining legal distinction.
THE BIOLOGICAL WEAPONS CONVENTION
The Biological Weapons Convention entered into force in 1975 and remains the cornerstone of international biological arms control. It prohibits the development, production, acquisition, stockpiling, and retention of biological agents or toxins except for prophylactic, protective, or other peaceful purposes.^10
Unlike the Chemical Weapons Convention, however, the BWC does not have an equivalent organization such as the Organisation for the Prohibition of Chemical Weapons (OPCW) that routinely conducts inspections of declared facilities.
Nor does it have an international equivalent to the International Atomic Energy Agency (IAEA), which monitors many aspects of civilian nuclear programs.
Instead, compliance relies primarily upon:
- national implementation;
- diplomatic engagement;
- voluntary confidence-building measures;
- scientific cooperation; and
- intelligence assessments.
For decades, governments have debated whether stronger verification mechanisms are technically feasible. Those discussions have become more active since the Ninth Review Conference of the BWC established a Working Group to revisit questions of compliance and verification after more than twenty years of limited formal progress.^11
WHY VERIFICATION IS SO DIFFICULT
Biological verification presents challenges that differ fundamentally from those associated with nuclear or chemical weapons.
Small Footprint
A sophisticated biological laboratory occupies a fraction of the space required for uranium enrichment or missile production.
Many advanced facilities are located within:
- universities;
- hospitals;
- pharmaceutical companies;
- agricultural institutes; and
- public-health laboratories.
Nothing about the exterior of a laboratory reveals whether research is defensive, commercial, academic, or prohibited.
Legitimate Research Uses Similar Technology
Equipment used to:
- manufacture vaccines,
- sequence viral genomes,
- identify new pathogens,
- develop diagnostic tests,
- or study antimicrobial resistance
may also be capable of supporting other forms of research if misused.
Because biotechnology serves overwhelmingly legitimate medical and scientific purposes, regulators cannot simply prohibit the underlying equipment.
Knowledge Travels Faster Than Equipment
Another complication is that biology depends heavily upon scientific expertise rather than specialized industrial infrastructure.
Researchers routinely collaborate internationally.
Scientific journals publish experimental methods.
Genetic sequence databases are publicly available.
Artificial intelligence increasingly assists in protein analysis, molecular modeling, and drug discovery.
The result is a scientific ecosystem in which information often moves more rapidly than regulatory systems.
THE TRANSPARENCY GAP
The Fauci hearing has revived discussion about transparency—not because Congress questioned the legitimacy of biomedical research itself, but because legislators examined how scientific decisions were documented, communicated, and overseen.
That distinction is important.
Transparency does not necessarily require governments to disclose classified national security research.
It does suggest that governments should be able to explain:
- who funds major biological research;
- which agencies oversee biosafety;
- what reporting requirements exist;
- how accidents are investigated;
- and how public confidence is maintained.
Many of these questions apply equally to the United States, Israel, Saudi Arabia, Qatar, the United Arab Emirates, Egypt, Jordan, and Iran.
THE MIDDLE EAST’S EMERGING CHALLENGE
Middle Eastern governments increasingly seek to become biotechnology leaders.
Several national development strategies now identify biotechnology as essential for:
- economic diversification;
- pharmaceutical independence;
- food security;
- precision medicine;
- pandemic preparedness;
- artificial intelligence applications; and
- advanced manufacturing.
These ambitions require attracting:
- foreign investment;
- multinational pharmaceutical companies;
- university partnerships;
- international clinical research;
- and highly skilled scientists.
Such collaboration depends heavily upon international confidence.
The more governments invest in advanced biological research, the greater the importance of demonstrating credible governance, biosafety standards, and institutional oversight.
THE NEXT PHASE OF INTERNATIONAL BIOSECURITY
Recent discussions within the Biological Weapons Convention increasingly emphasize transparency rather than intrusive inspections.
Experts have proposed strengthening:
- voluntary peer-review exercises;
- confidence-building measures (CBMs);
- national reporting;
- biosafety standards;
- scientific advisory mechanisms; and
- cooperative compliance initiatives.
These proposals acknowledge a practical reality:
Perfect verification may be impossible.
Greater transparency, however, may reduce uncertainty while preserving legitimate scientific collaboration.^12
JAFAJ STRATEGIC ASSESSMENT
The debate initiated by the Fauci hearing should not be viewed solely through the lens of COVID-19.
Its broader significance is institutional.
Congress is asking questions that every technologically advanced government will eventually confront:
- Who oversees high-risk biological research?
- How much information should be public?
- What constitutes adequate independent oversight?
- How should governments balance scientific openness against national security?
- What level of transparency is necessary to sustain public trust?
These questions are no longer confined to Washington.
They are becoming central issues for every nation investing in biotechnology.
The Middle East is unlikely to experience sweeping regulatory change immediately. Nevertheless, governments seeking international investment and scientific partnerships may find that transparency itself becomes a competitive advantage.
Those able to demonstrate robust governance frameworks, clear biosafety procedures, and internationally recognized standards are likely to enjoy greater scientific credibility than states whose laboratory oversight remains opaque.
This is not simply a public-health issue.
It is becoming a matter of economic competitiveness, diplomatic credibility, and national security.
STRATEGIC OUTLOOK — WHO CHANGES COURSE?
KEY JUDGMENTS
- The immediate impact of the Fauci hearing is likely to be political within the United States, but its longer-term effect may be institutional, influencing laboratory governance and oversight worldwide.
- Middle Eastern governments are unlikely to fundamentally alter their biological research programs. They may, however, strengthen biosafety governance, reporting mechanisms, and public messaging as international scrutiny increases.
- Future competition in biotechnology is likely to be measured not only by scientific capability, but also by the credibility of oversight systems, transparency practices, and regulatory institutions.
- The next decade may witness the emergence of biosecurity diplomacy as a distinct element of international relations, much as nuclear diplomacy became during the Cold War.
THE UNITED STATES
Congress has entered a new phase of oversight.
Regardless of how future administrations interpret COVID-era decisions, bipartisan interest in biosafety, gain-of-function oversight, federal research funding, and laboratory governance has increased significantly since the pandemic. Multiple congressional committees have examined:
- federal grant oversight;
- international research partnerships;
- agency recordkeeping;
- laboratory safety;
- pandemic preparedness;
- executive branch transparency; and
- interagency coordination.^13
Future legislation could include:
- expanded reporting requirements for federally funded pathogen research;
- stronger oversight of overseas biological research partnerships;
- revised grant disclosure requirements;
- enhanced whistleblower protections;
- updated biosafety standards; and
- periodic congressional review of high-risk biological research.
The precise legislative outcome remains uncertain, but congressional attention to these issues is unlikely to diminish.
ISRAEL
Israel is unlikely to modify the operational mission of the Israel Institute for Biological Research or its broader biodefense enterprise.
Instead, the likely changes—if any—would involve:
- expanded scientific diplomacy;
- increased participation in international biosafety initiatives;
- greater emphasis on defensive research;
- strengthened public communication concerning civilian biomedical research.
Israel’s biotechnology sector has become increasingly integrated with its pharmaceutical industry, universities, cybersecurity ecosystem, and defense technology base.
Because Israel already operates within a mature national security framework, its primary challenge will likely involve balancing legitimate national security secrecy with international expectations for transparency.
SAUDI ARABIA
Saudi Arabia’s Vision 2030 strategy identifies biotechnology as an important economic growth sector.
Future investments are likely to emphasize:
- domestic pharmaceutical manufacturing;
- vaccine production;
- genomic medicine;
- biotechnology commercialization;
- medical innovation.
The Kingdom has invested heavily in attracting international scientific partnerships.
Consequently, Saudi Arabia has a strategic incentive to demonstrate internationally recognized biosafety standards and regulatory credibility.
Transparency increasingly supports investment.
Investment increasingly supports national power.
UNITED ARAB EMIRATES
The UAE has consistently positioned itself as a regional technology leader.
Its comparative advantage lies not in military biological research but in:
- artificial intelligence;
- genomic medicine;
- advanced diagnostics;
- biotechnology entrepreneurship;
- international scientific collaboration.
Greater global attention to laboratory governance is therefore more likely to reinforce existing Emirati policies than fundamentally alter them.
The UAE’s objective remains attracting international partners who value regulatory stability.
QATAR
Qatar’s long-term strategy centers upon precision medicine and genomic science.
Doha has invested heavily in:
- national genomic databases;
- personalized medicine;
- biomedical education;
- international academic partnerships.
These investments depend upon scientific credibility.
Accordingly, Qatar has an incentive to support international biosafety norms and transparent governance while maintaining competitiveness within the Gulf research sector.
EGYPT
Egypt occupies a unique strategic position.
Its disease surveillance institutions routinely cooperate with international organizations monitoring outbreaks affecting Africa, Europe, and the Middle East.
Egypt therefore has significant interest in maintaining:
- international confidence;
- laboratory accreditation;
- regional surveillance cooperation;
- emergency response capability.
Future congressional attention to international research partnerships may indirectly affect institutions participating in multinational disease surveillance programs.
JORDAN
Jordan’s strategic importance derives less from laboratory scale than from geography.
The Kingdom borders areas affected by prolonged conflict, refugee displacement, and recurring humanitarian emergencies.
Jordan will likely continue emphasizing:
- regional disease surveillance;
- refugee health;
- international public health cooperation;
- biosafety capacity building.
Its strongest comparative advantage lies in multilateral cooperation rather than biotechnology commercialization.
IRAN
Iran presents the most complicated case.
International attention toward Iranian scientific activities has traditionally focused upon its nuclear program.
Biotechnology has received comparatively less scrutiny.
Nevertheless, Iran has steadily expanded domestic biomedical research, vaccine production, pharmaceutical manufacturing, and biotechnology under conditions shaped by international sanctions.
Future U.S. congressional investigations concerning overseas biological research are unlikely to directly affect Iranian institutions.
Politically, however, Tehran may seek to portray congressional disputes over COVID-era policies as evidence that Western governments themselves continue to debate standards of laboratory oversight and pandemic decision-making.
At the same time, Iran can be expected to resist external efforts that it perceives as expanding international inspection authorities beyond existing treaty obligations.
TÜRKİYE
Türkiye has invested substantially in biotechnology, vaccine development, and domestic pharmaceutical manufacturing over the past decade.
Ankara increasingly views biotechnology as:
- an industrial capability;
- an export opportunity;
- an element of national resilience.
Türkiye is therefore likely to support stronger biosafety standards while remaining cautious toward any international mechanisms perceived as infringing upon national sovereignty.
THE WORLD HEALTH ORGANIZATION
The WHO is likely to continue emphasizing:
- laboratory biosafety;
- laboratory biosecurity;
- outbreak reporting;
- international scientific cooperation;
- preparedness planning.
However, the WHO possesses limited authority to compel sovereign governments to disclose laboratory activities beyond obligations established through international agreements.
Consequently, future reforms are more likely to emerge through national legislation than through WHO mandates.
THE BIOLOGICAL WEAPONS CONVENTION
Perhaps the most important long-term implications involve the Biological Weapons Convention itself.
Since COVID-19, participating states have increasingly discussed:
- confidence-building measures;
- voluntary peer review;
- scientific advisory mechanisms;
- enhanced transparency;
- compliance discussions;
- institutional strengthening.
None of these initiatives would create an inspection system comparable to the International Atomic Energy Agency.
They would, however, strengthen international confidence while preserving legitimate scientific research.^14
THE NEXT FRONTIER: BIOSECURITY DIPLOMACY
The Cold War transformed nuclear weapons into instruments of diplomacy.
The twenty-first century may witness a similar evolution regarding biotechnology.
Future alliances may increasingly consider:
- pandemic preparedness;
- pharmaceutical manufacturing;
- genomic research;
- laboratory security;
- biotechnology supply chains;
- scientific resilience.
Countries capable of demonstrating credible governance may enjoy diplomatic advantages extending beyond public health.
Laboratory credibility could become an element of national influence.
JAFAJ STRATEGIC ASSESSMENT
The Fauci hearing should not be viewed as the conclusion of the COVID debate.
Rather, it represents the beginning of a broader discussion concerning governance of advanced biological research.
The strategic issue is no longer whether biotechnology should expand.
It will.
The more consequential question is how governments intend to govern it.
The Middle East illustrates this transition clearly.
Nearly every major regional power is investing in biotechnology.
None can fully separate scientific progress from national security.
None can avoid questions regarding transparency indefinitely.
The countries that successfully balance innovation, security, and public accountability are likely to emerge as regional leaders in biotechnology over the next decade.
For policymakers, the lesson extends well beyond COVID-19.
The future competition among states may not be determined solely by who develops the most advanced biological technologies.
It may instead be determined by who develops the institutions capable of governing those technologies responsibly.
That is the enduring strategic implication of the debate now unfolding in Washington.
CONCLUSION
The July 2026 congressional hearing involving Dr. Anthony Fauci is best understood not as an endpoint in the debate over the COVID-19 pandemic, but as an inflection point in the global conversation about biological governance. While political attention has focused on testimony, documents, and accountability, the more lasting consequence may be a renewed examination of how nations supervise research involving dangerous pathogens, fund advanced laboratories, and build public confidence in scientific institutions.
For the Middle East, this discussion arrives at a pivotal moment. Governments across the region are investing heavily in biotechnology, precision medicine, vaccine development, and genomic research as part of broader economic and national security strategies. These investments promise substantial public health and economic benefits, but they also increase expectations for robust oversight and credible biosafety frameworks.
The strategic contest ahead is unlikely to be defined by the number of laboratories a nation possesses. It will be shaped by the quality of its governance, the transparency of its institutions, and its ability to reassure both domestic populations and international partners that powerful biological capabilities are being managed responsibly.
FOOTNOTES
- U.S. Senate Committee on Homeland Security and Governmental Affairs, Testimony of Anthony Fauci, hearing held July 29, 2026.
- Axios, “The Most Fiery Moments from Fauci’s Senate Hearing,” July 29, 2026.
- The Washington Post, “Fauci’s Diary Reveals His Thoughts on a ‘Rambling’ Trump and His Own Fame,” July 28, 2026.
- The New Yorker, “The Failures of the Fauci Hearing,” August 10, 2026 (advance publication).
- King Abdullah University of Science and Technology (KAUST), “Research” and “Institutional Biosafety and Bioethics Committee,” accessed August 2026.
- King Abdullah University of Science and Technology, “Groundbreaking for First R&D Vaccine Center in the Middle East,” December 17, 2018; KAUST Innovation, “Agreement Signed for Building of the Saudi Vaccine and Biomanufacturing Center.”
- Khalid A. Fakhro et al., “The Qatar Genome: A Population-Specific Tool for Precision Medicine in the Middle East,” 2018; Qatar University, “National Research Centers.”
- Pasteur Institute of Iran, institutional history and mission (background information).
- James Revill, Verifying the BWC: A Primer (Geneva: United Nations Institute for Disarmament Research, October 17, 2023). The report explains that the Biological Weapons Convention lacks a formal verification regime and discusses contemporary approaches to compliance and monitoring.
- United Nations Office for Disarmament Affairs, Biological Weapons Convention (BWC) Confidence-Building Measures Portal; Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction.
- Ajey Lele et al., The Focus and Function of BWC Verification (Geneva: United Nations Institute for Disarmament Research, December 5, 2024). The report summarizes ongoing international discussions on compliance and verification under the BWC Working Group.
- María J. Espona, Voluntary Transparency Initiatives: The Case of Peer Review Exercises in the Context of the BWC (Geneva: United Nations Institute for Disarmament Research, August 19, 2024). The study examines voluntary transparency initiatives and confidence-building measures as practical approaches in the absence of a formal verification system.
- U.S. Congress, House Select Subcommittee on the Coronavirus Pandemic, interim and final oversight reports (2023–2025); U.S. Senate Committee on Homeland Security and Governmental Affairs, hearing materials related to pandemic oversight and federal biosafety governance.
- United Nations Office for Disarmament Affairs, Biological Weapons Convention Working Group documentation and meeting reports (2023–2026); United Nations Institute for Disarmament Research (UNIDIR), publications on verification, confidence-building measures, and institutional strengthening under the Biological Weapons Convention.